Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 346 News
1 - 10of about 346 News
September 20, 2023
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues 1.75 billion euro hybrid bond
READ MORE
September 19, 2023
Dr. Jost Reinhard appointed new head of Investor Relations at Bayer
READ MORE
September 18, 2023
Not intended for UK Media
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
READ MORE
August 29, 2023
Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn
READ MORE
August 28, 2023
Not intended for UK Media
BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
READ MORE
August 24, 2023
Not intended for U.S. and UK Media
Additional studies with finerenone across a wide range of heart failure patients initiated
READ MORE
August 21, 2023
Heike Prinz appointed to Board of Management of Bayer AG
READ MORE
August 08, 2023
Bayer Group:
Second quarter impacted by declines in glyphosate business
READ MORE
July 24, 2023
Bayer lowers full-year outlook
READ MORE
June 29, 2023
Not intended for U.S. and UK Media
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years
READ MORE
1 - 10of about 346 News
1 - 10of about 346 News

 

Subscribe To Our Latest News 

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more